BioCryst Taps Ipsen Exec as CSO to Accelerate Rare Disease Pipeline
Event summary
- BioCryst appoints David W. Jenkins as Chief Scientific Officer, effective July 15, 2026.
- Jenkins previously led R&D and external innovation at Ipsen, adding 35+ assets to its pipeline.
- New role focuses on leveraging external partnerships to accelerate rare disease therapies.
- Jenkins will report to Dr. Sandeep Menon, Chief Research and Development Officer.
The big picture
BioCryst's appointment of Jenkins signals a strategic pivot from in-house R&D to a more externally focused innovation model, aligning with broader industry trends toward collaborative drug development. This move could enhance BioCryst's ability to compete in the rare disease space, where speed and capital efficiency are critical.
What we're watching
- Pipeline Acceleration
- How Jenkins' experience at Ipsen will impact BioCryst's ability to rapidly integrate external innovations into its pipeline.
- Capital Efficiency
- Whether the shift to a more partnership-driven model can reduce R&D costs while maintaining therapeutic quality.
- Commercial Viability
- The pace at which BioCryst can translate its expanded pipeline into market-ready rare disease treatments.
Related topics